Credit: Shutterstock photoCatalyst Pharmaceuticals, Inc.CPRX was a big mover last session, as its shares rose almost 7% on the day. The rally came on the back of the company's agreement with the FDA on a confirmatory Phase 3 study protocol for Firdapse in Lambert-Eaton myasthenic syndrome (LEMS). This led to far more shares changing hands than in a normal session. This continues the recent uptrend of the company, as the stock is now up 10% in the past one-month time frame.
Over the last 30 days, the company witnessed one positive estimate revision and the Zacks Consensus Estimate also moved higher, suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday's jump can turn into more strength down the road.
Catalyst Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
CATALYST PHARMA Price
CATALYST PHARMA Price | CATALYST PHARMA Quote
A better-ranked med-drugs stock is Juniper Pharmaceuticals, Inc. JNP , sporting a Zacks Rank #1(Strong Buy).
Is CPRX going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CATALYST PHARMA (CPRX): Free Stock Analysis Report
JUNIPER PHARMA (JNP): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
